Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax-Navitoclax with Cladribine-based Salvage in R/R AML
NCT06007911Phase 1Withdrawn
- Sponsor
- Medical College of Wisconsin
- Start
- Aug 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of navitoclax in acute myeloid leukemia (AML) (2 arms), sponsored by Medical College of Wisconsin. Primary endpoint: Recommended Phase 2 Dose of Navitoclax up to 3 years. Planned start Aug 2024; status: withdrawn.
02
Drugs
navitoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06007911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06007911.